Diabetes | Page 8 of 8 | Links Medicus Content Curation & Alerts in Medicine

RCT | Effect of a comprehensive telehealth intervention vs. telemonitoring and care coordination in patients with persistently poor type 2 diabetes control.

9 Aug, 2022 | 12:44h | UTC

Effect of a Comprehensive Telehealth Intervention vs Telemonitoring and Care Coordination in Patients With Persistently Poor Type 2 Diabetes Control: A Randomized Clinical Trial – JAMA Internal Medicine (link to abstract – $ for full-text)

Commentary: Comprehensive telehealth intervention effective for reducing HbA1c in poorly controlled diabetes – Physician’s Weekly

Commentary on Twitter

A comprehensive telehealth intervention improved HbA1c in persistently poorly-controlled type 2 diabetes compared to a simpler telehealth intervention; the comprehensive telehealth approach may warrant implementation in systems with appropriate resources. https://t.co/qXnuclyipQ

— JAMA Internal Medicine (@JAMAInternalMed) July 29, 2022

Systematic Review | Diabetes mellitus and perioperative outcomes.

9 Aug, 2022 | 12:28h | UTC

Diabetes mellitus and perioperative outcomes: a scoping review of the literature – British Journal of Anaesthesia

RCT | Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes.

8 Aug, 2022 | 11:56h | UTC

Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trial – Diabetes, Obesity and Metabolism

M-A | Effectiveness and safety of new oral and injectable agents for in-hospital management of type 2 diabetes in general wards.

8 Aug, 2022 | 11:37h | UTC

Effectiveness and safety of new oral and injectable agents for in-hospital management of type 2 diabetes in general wards: systematic review and meta-analysis – Diabetes Research and Clinical Practice

Cohort study | Adults with Type 2 Diabetes and nonalcoholic fatty liver disease are at increased risk of severe hypoglycemia.

5 Aug, 2022 | 14:30h | UTC

Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease – JAMA Network Open

Commentary: Consider Fatty Liver Disease for Hypoglycemia Risk in Diabetes – JAMA Network Open (free registration required)

Commentary on Twitter

In this cohort study, participants with type 2 diabetes and nonalcoholic fatty liver disease without cirrhosis had a 26% increased risk of severe hypoglycemia diabetes independent of obesity status. https://t.co/Zh9tHkOmOa

— JAMA Network Open (@JAMANetworkOpen) February 23, 2022

M-A | GLP1 receptor agonists are associated with increased risk of progression of retinopathy in patients with type 2 diabetes.

2 Aug, 2022 | 12:32h | UTC

Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes – A systematic review and meta-analysis – Journal of Diabetes and its Complications (link to abstract – $ for full-text)

Commentary: GLP1 RA use tied to increased risk of rapidly worsening retinopathy in type 2 diabetes – Medical Dialogues

RCT | Safety and efficacy of Tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan.

2 Aug, 2022 | 12:05h | UTC

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

See also (note: the dulaglutide dosage used in this trial was probably suboptimal): Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

Tirzepatide Once Weekly for the Treatment of Obesity – New England Journal of Medicine

Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis – Diabetologia

Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis – Nature Medicine

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary on Twitter

Online—Safety and efficacy of #tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 #diabetes in #Japan (#SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial https://t.co/r4v4QUsl5q #T2D pic.twitter.com/k6ihWy2vem

— The Lancet Diabetes & Endocrinology (@TheLancetEndo) July 31, 2022